105 The determination of the synergistic antibiotic combinations for the treatment of multiresistant Pseudomonas aeruginosa isolates from CF patients  by Sener, B. et al.
4. Microbiology 
F~How long can aminoglycosides be deferred using IMactam alone 
for Pseudomonas aeruginosa (PA) in children with CF? 
E. Newberry, P. Ashcroft, B. Sanyal, T.J. David, L. Patel. Paediatric Cystic Fibrosis 
Service, Central Manchester and Manchester Children's University Hospitals, UK 
Aims: To study the time to emergence of ceftazidime (Caz) resistant P. aeruginosa (r- 
PA) in patients managed through childhood with elective intravenous antibiotic regimen 
and preference for monotherapy with this antibiotic. 
Methods: Children diagnosed with CF since 1982 and found to have PA were studied 
retrospectively (27 m, 28 f). Patients were managed at a tertiary centre with elective 
3-monthly IV antibiotic regimen for 1 st isolation of PA (1 st PA) until PA clearance (no 
PA in the preceding 12 m) and again for PA colonization. For each course, treatment was 
determined from the PA susceptibility pattern over the preceding 3 m, the preference 
being Caz. Aminoglycosides were added to the treatment regimen when Caz r-PA 
emerged. Sputum results were examined for 1 st PA; PA clearance, PA colonization 
(repeated and persistent isolation); and Caz r-PA. 
Results: Results are shown in the table. 
n median (range), y
Age at 1 st PA 55 2.1 (0.3 7.9) 
Age at PA coloinsation 43 6.7 (0.5 14.8) 
Age at Caz resistant PA 37 10.1 (2.5 15.5) 
Interval to Caz resistant PA after colon/sat/on 35 2.6 (0.1 11.8) 
At 1 st PA, none were resistant o Caz. 18/55 patients had no PA clearance and thus 
had colonization from 1 st PA. 37/55 had PA clearance after treatment for 1.3y (1 5) 
and of these, 25 had PA colonization after a PA free period of 6.5 y (1.2 14.5). Two 
patients had Caz r PA at start of colonization. 
Conclusions: In comparison to alternative regimens including aminoglycosides from 
colonization, a regimen with a preference for monotherapy with Caz permitted eferring 
the addition of aminoglycosides by a median duration of 2.6 years. Thus patients were 
spared aminoglycosides and the cumulative dose was reduced by an average of 10 
courses. 
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F~The determination of the synergistic antibiotic combinations 
for the treatment of multiresistant Pseudomonas aeruginosa 
isolates from CF patients 
B. Sener 1 , S. Ak 1 , E. Yalcin 2, S. Pekcan 2, D. Dogru 2, A. Aslan 2, U. Ozcelik 2, 
N. Kiper 2. 1Dept. of  Clinical Microbiology, 2pediatric Pulmonology Unit, 
Hacettepe Univ. Medical Faculty, Ankara, Turkey 
Introduction: Treatment failure due to antibiotic resistant Pseudomonas eruginosa 
(PA) is a frequent outcome in CE The best therapeutic approach for the treatment of 
such infections eems to be the use of combination antibiotic therapy. The aim of this 
study is to determine the optimal bactericidal combination by multiple combination 
bactericidal testing (MCBT) for multiresistant CF PA isolates. 
Methods: The bactericidal activities of 40 multiresistant PA isolates were deter- 
mined for single and double antibiotics, to give 19 different combinations, by 
MCBT using fixed antibiotic concentrations based on estimates of the average peak 
levels in serum after single iv administration. Tobramycin 200 gg/ml denoted the 
concentration in lungs after inhalation. 
Results: The % bactericidal activity of  single antibiotics against the test iso- 
lates were: aztreonam 27.5, ceftazidime 27.5, cefepime 40, meropenem 75, 
ciprofloxacin 77.5, amikacin 75, tobramycin 4 gg/ml 77.5, tobramycin 200 gg/ml 
92.5. Combination testing revealed that ciprofloxacin+tobramycin 200 and 
meropenem+amikacin were 95% bactericidal, followed by cefepime+amikacin 
92.5%, meropenem+tobramycin 200 (87.5%), cefepime+tobramycin 200 85%, 
ciprofloxacin+amikacin 77.5%, ciprofloxacin+ceftazidime 72.5%. 
Conclusion: Double antibiotic combinations are more likely than single antibiotics 
to be bactericidal in vitro against multiresistant PA. The most effective combinations 
in our CF PA population were ciprofloxacin+inhaled tobramycin (200 gg/ml) and 
meropenem+amikacin. Overall data indicated that inhaled tobramycin significantly 
enhanced the bactericidal activity of  the second drug. 
I • A  longitudinal study.of the antimicrobial resistance of 
Pseudomonas aerugmosa in a Turkish CF Unit 
O. Torun 1 , B. Sener 1, E. Yalcin 2, S. Pekcan 2, D. Dogru 2, U. Ozcelik 2, N. K/per 2 . 1Dept of 
Clinical Microbiology, 2pediatric Pulmonology Unit, Hacettepe Univ Medical Faculty, Ankara, 
Turkey 
Intl'O4UC~on: An important consequence of antibiotic therapy of chronic Pseudomonas aeruginosa 
(PA) infection in CF is the increasing rate of antibiotic resistance. Tiffs study was aimed to investigate 
the rate of antibiotic resistance in PA isolated from a group of Turkish CF patients. 
Metho4s: A total of 195 CF patients were retrospectively analysed for PA isolation rate and suscepti- 
bility. The in vitro efficacy of aztreonanl, cefiazidime, cefepime, infipenem, anfikacin, tobramycin and 
ciprofloxacin against PA isolated between 1995~005 were investigated by disk diffiasion susceptibility 
testing according to CLSI guidelines. Data were analyzed in terms of resistance on 5 yearly basis. 
One to three isolates with different phenotypic l/aracteristics/year/patient w reconsidered for the 
analysis. 
Results: PA was isolated from 93 cases (47.7%). The number of isolates were 35 in 1995, 49 in 2000 
and 113 in 2005. The rates of resistances were given in the table. Multiresistant isolates were 5.7% 
in 1995, 4% in 2000 and 8.9% in 2005. Inducible beta-lactamase activity was detected in 20.4% of 
isolates in 2000 and 30.0% in 2005. 
Antibiotics 1995 (% R) 2000 (°/~R) 2005 (°/~R) 
Aztt~onaln 17.1 26.5 29.2 
Cellazidime 20.0 14.3 27.4 
Cefepime 12.2 15.0 
Imipenem 5.7 12.2 16.8 
Amikacin 11.4 18.4 11.5 
Tobramycin 22.4 14.1 
Ciprofloxacin 8.6 12.2 13.3 
Conclusion: Tiffs study indicates the increasing resistance specially to beta-lactanl antibiotics 
amongst PA isolates in our CF population. The decreasing rate of resistance to aminoglycosides 
may be altributed to the use of fffl/aled tobramycin starting from the end of 2004. The prudent use 
of antibiotics and mointorization of resistance should be actively considered. 
1• Mucoid phenotype of Pseudomonas aeruginosa isolates is 
associated with decreased antimicrobial resistance 
D.J. Waine 1 , G. Smith 2, J. Whitehouse 1 , D. Honeybourne 1 . 1 West Midlands Adult 
CF Unit, 2 Dept of Microbiology, Heart of England Foundation Trust, Birmingham, 
UK 
Introduction: The majority of adult patients with cystic fibrosis (CF) are colonized 
with Pseudomonas aeruginosa nd a significant proportion of  them have a mucoid 
phenotype. Some studies have shown the mucoid phenotype to be associated 
with increased ant/microbial resistance [1] whereas others have found decreased 
ant/microbial resistance [2]. 
Aims: We audited retrospective resistance data from our CF population to investi- 
gate the association between mucoid phenotype and ant/microbial resistance. 
Methods: Data from 1876 B aeruginosa isolates, from 194 adult CF patients, 
were analyzed and the percentage of antibiotics (usually a standard panel of 9) to 
which they had been tested and found resistant, according to standard isc-diffusion 
method on agar, was recorded. 
Results: There were 1061 mucoid isolates and 815 non-mucoid isolates. The median 
percentage of antibiotics to which the isolates were resistant was 0% (inter-quartile 
range 0 22%) for the mucoid isolates and 44% (interquartile range 0 100%) for the 
non-mucoid isolates (p < 0.001). For each of the 9 antibiotics, non-mucoid isolates 
were significantly more likely than mucoid isolates to be resistant (p < 0.001). 
Conclusions: Non-mucoid isolates were significantly more resistant o antimicro- 
bials than mucoid isolates. This may be because mucoid isolates are protected from 
antimicrobials in vivo by the mucoid alginate and therefore lose the more typical 
antibiotic resistance systems needed to confer resistance when tested in-vitro. 
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